FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199285265> ?p ?o ?g. }

• W3199285265 abstract "Background: Dl-3-n-Butylphthalide (NBP) has the potential to improve clinical outcomes in acute ischemic stroke patients by improving collateral circulation. We aimed to evaluate the efficacy and safety of NBP in patients with non-disabling minor ischemic stroke and transient ischemic attack (TIA). Methods: The BRIDGE (the observation study on clinical effectiveness of NBP on patients with non-disabling ischemic cerebrovascular disease) is a prospective registry to monitor the efficacy and safety of NBP therapy in acute non-disabling ischemic stroke or high-risk TIA. Non-disabling minor ischemic stroke patients within 48 h were enrolled across 51 stroke centers in China. We divided patients into NBP compliance or non-compliance groups according to their adherence to NBP. The primary outcome was the favorable functional outcome at 90 days, defined as a modified Rankin scale (mRS) <2. Results: Between 10th October 2016 and 25th June 2019, 3,118 patients were included in this analysis. In multivariable analysis, Between 10th October 2016 and 25th June 2019, 3,118 patients were included in this analysis. In multivariable analysis, after adjusting for common risk factors and demographic factors, NBP-compliance group has a higher proportion of favorable functional outcome (92.1 vs. 87.4%, adjusted odds ratio 2.00, 95% confidence interval, 1.50–2.65), and a higher stroke recurrence rate (2.40 vs. 0.31%, adjusted odds ratio 8.86, 95% confidence interval, 3.37–23.30) than the NBP-non-compliance group. There was no significant difference in death and intracranial hemorrhage rate between the two groups. In subgroup analysis, patients with National Institutes of Health Stroke Scale (NIHSS) scores from 3 to 5 who complied to NBP therapy had a higher rate of favorable functional outcomes than the NBP-non-compliance group. [88.82 vs. 76.21%, adjusted odds ratio 2.52 (1.81–3.50), adjusted interaction P = 0.00]. Conclusion: In non-disabling minor ischemic stroke or TIA patients, compliance with NBP therapy led to better 90-day functional outcomes despite a higher risk of recurrence, and this effect seems to be stronger in patients with NIHSS scores of 3-5. Further large randomized, double-blind controlled studies to analyse the association between NBP and functional outcome is warranted in the coming future." @default.
• W3199285265 created "2021-09-27" @default.
• W3199285265 creator A5040286509 @default.
• W3199285265 creator A5055707963 @default.
• W3199285265 creator A5077290418 @default.
• W3199285265 creator A5081921925 @default.
• W3199285265 creator A5083506982 @default.
• W3199285265 creator A5091443199 @default.
• W3199285265 date "2021-09-22" @default.
• W3199285265 modified "2023-10-16" @default.
• W3199285265 title "Efficacy and Safety of Adherence to dl-3-n-Butylphthalide Treatment in Patients With Non-disabling Minor Stroke and TIA—Analysis From a Nationwide, Multicenter Registry" @default.
• W3199285265 cites W1480729244 @default.
• W3199285265 cites W1968674888 @default.
• W3199285265 cites W1999357998 @default.
• W3199285265 cites W2058495023 @default.
• W3199285265 cites W2070426582 @default.
• W3199285265 cites W2081615170 @default.
• W3199285265 cites W2092001267 @default.
• W3199285265 cites W2101621119 @default.
• W3199285265 cites W2107181967 @default.
• W3199285265 cites W2110077551 @default.
• W3199285265 cites W2111089169 @default.
• W3199285265 cites W2118663843 @default.
• W3199285265 cites W2120531185 @default.
• W3199285265 cites W2133784818 @default.
• W3199285265 cites W2134341342 @default.
• W3199285265 cites W2135901678 @default.
• W3199285265 cites W2140048343 @default.
• W3199285265 cites W2145282126 @default.
• W3199285265 cites W2156108549 @default.
• W3199285265 cites W2165328975 @default.
• W3199285265 cites W2165920141 @default.
• W3199285265 cites W2171058244 @default.
• W3199285265 cites W2192451241 @default.
• W3199285265 cites W2236126349 @default.
• W3199285265 cites W2325435112 @default.
• W3199285265 cites W2353930261 @default.
• W3199285265 cites W2787867590 @default.
• W3199285265 cites W2803728669 @default.
• W3199285265 cites W2806156457 @default.
• W3199285265 cites W2808046270 @default.
• W3199285265 cites W2944491145 @default.
• W3199285265 cites W2976933139 @default.
• W3199285265 cites W3087093923 @default.
• W3199285265 cites W3091926330 @default.
• W3199285265 cites W3094179140 @default.
• W3199285265 cites W74646391 @default.
• W3199285265 doi "https://doi.org/10.3389/fneur.2021.720664" @default.
• W3199285265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8492907" @default.
• W3199285265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34630292" @default.
• W3199285265 hasPublicationYear "2021" @default.
• W3199285265 type Work @default.
• W3199285265 sameAs 3199285265 @default.
• W3199285265 citedByCount "6" @default.
• W3199285265 countsByYear W31992852652022 @default.
• W3199285265 countsByYear W31992852652023 @default.
• W3199285265 crossrefType "journal-article" @default.
• W3199285265 hasAuthorship W3199285265A5040286509 @default.
• W3199285265 hasAuthorship W3199285265A5055707963 @default.
• W3199285265 hasAuthorship W3199285265A5077290418 @default.
• W3199285265 hasAuthorship W3199285265A5081921925 @default.
• W3199285265 hasAuthorship W3199285265A5083506982 @default.
• W3199285265 hasAuthorship W3199285265A5091443199 @default.
• W3199285265 hasBestOaLocation W31992852651 @default.
• W3199285265 hasConcept C126322002 @default.
• W3199285265 hasConcept C127413603 @default.
• W3199285265 hasConcept C156957248 @default.
• W3199285265 hasConcept C1862650 @default.
• W3199285265 hasConcept C2780645631 @default.
• W3199285265 hasConcept C2780931571 @default.
• W3199285265 hasConcept C3020199598 @default.
• W3199285265 hasConcept C44249647 @default.
• W3199285265 hasConcept C541997718 @default.
• W3199285265 hasConcept C71924100 @default.
• W3199285265 hasConcept C78519656 @default.
• W3199285265 hasConceptScore W3199285265C126322002 @default.
• W3199285265 hasConceptScore W3199285265C127413603 @default.
• W3199285265 hasConceptScore W3199285265C156957248 @default.
• W3199285265 hasConceptScore W3199285265C1862650 @default.
• W3199285265 hasConceptScore W3199285265C2780645631 @default.
• W3199285265 hasConceptScore W3199285265C2780931571 @default.
• W3199285265 hasConceptScore W3199285265C3020199598 @default.
• W3199285265 hasConceptScore W3199285265C44249647 @default.
• W3199285265 hasConceptScore W3199285265C541997718 @default.
• W3199285265 hasConceptScore W3199285265C71924100 @default.
• W3199285265 hasConceptScore W3199285265C78519656 @default.
• W3199285265 hasLocation W31992852651 @default.
• W3199285265 hasLocation W31992852652 @default.
• W3199285265 hasLocation W31992852653 @default.
• W3199285265 hasLocation W31992852654 @default.
• W3199285265 hasOpenAccess W3199285265 @default.
• W3199285265 hasPrimaryLocation W31992852651 @default.
• W3199285265 hasRelatedWork W1974032428 @default.
• W3199285265 hasRelatedWork W1994858555 @default.
• W3199285265 hasRelatedWork W2122595195 @default.
• W3199285265 hasRelatedWork W2128703381 @default.
• W3199285265 hasRelatedWork W2158458852 @default.
• W3199285265 hasRelatedWork W2339958467 @default.
• W3199285265 hasRelatedWork W2576973703 @default.
• W3199285265 hasRelatedWork W2745205964 @default.

• next